Mutant p53 mediated induction of cell cycle arrest and apoptosis at G1 phase by 9-hydroxyellipticine

Anticancer Research

Volumn 19, Issue 4 B, 1999, Pages 3099-3108

  Sugikawa, Emiko ^a   Hosoi, Takeshi ^a   Yazaki, Naoko ^a   Gamanuma, Michiko ^a   Nakanishi, Noriyuki ^a   Ohashi, Motoaki ^a  

^a MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

Author keywords

9 hydroxyellipricine; Apoptosis; bax; G1 phase; Mutant p53

Indexed keywords

9 HYDROXYELLIPTICINE; ANTINEOPLASTIC ALKALOID; DOXORUBICIN; MESSENGER RNA; MUTANT PROTEIN; PROTEIN BAX; PROTEIN P53; UNCLASSIFIED DRUG; WAFL;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE; CELL CYCLE G1 PHASE; CENTRIFUGATION; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

APOPTOSIS; BASE SEQUENCE; BCL-2-ASSOCIATED X PROTEIN; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DNA PRIMERS; ELLIPTICINES; G1 PHASE; HUMANS; MUTATION; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, MESSENGER; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 0033452649     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Tay DLM, Bhathal PS, Fox R M: Quantitation of G0 and G1 phase cells in primary carcinomas. Antibody to M1 subunit of ribonucleotide reductase shows G 1 phase restriction point block. J Clin Inves 87: 519-527, 1991.
2. Gorczyca W, Gong J, rdelt B, Traganos F and Darzynkiewicz Z: The cell cycle related differences in susceptibility of HL-60 cells to apoptosis induced by various antitumor agents. Cancer Res 53: 3186-3192, 1993.
3. Boekkerink JP, De Abreu RA, Bakker MA, Hulscher TW, van Baal JM., Schretlen ED and De Bruijn CH: Effects of methotrexate on purine and pyrimidine metabolism and cell-kinetic parameters in human malignant lymphoblasts of different lineages. Biochem Pharmacol 37: 2329-2338, 1988.
4. Ling Y, El-Naggar AK, Priebe W and Perez-Soler R: Cell cycle-dependent cytotoxicity, G2/M phase arrest, and disruption of p;34Cdc2/cyclin B1 activity induced by doxorubicin in synchronized P388 cells. Mol Pharmacol 49: 832-841, 1996.
5. Lock RB and Ross WE: Inhibition of p34Cdc2 kinase activity by etoposide or irradiation as a mechanism of G2 arrest in chinese hamster ovary cells. Cancer Res 50: 3761-3766, 1990.
6. Inaba M, Mitsuhashi J, Kawada S and Nakano H: Different modes of cell-killing action between DNA topoisomerase I and II inhibitors revealed by kinetic analysis. Jpn J Cancer Res 85: 187-193, 1994.
7. Bino GD, Skierski JS and Darzynkiewicz Z: Diverse effects of camptothecin, an inhibitor of topoisomerase I, on the cell cycle of lymphocytic (L1210, Molt-4) and mylogenous (HL-60, KG1) leukemic cells. Cancer Res 50: 5746-5750, 1990.
8. Gong J, Li X and Darzynkiewicz Z: Different patterns of apoptosis of HL-60 cells induced by cycloheximide and camptothecin. J Cell Physiol 157: 263-270, 1993.
9. Lane DP: A death in the life of p53. Nature 362: 786-787, 1993.
10. Ryan JJ, Danish R, Gottlieb CA, and Clarke MF: Cell cycle analysis of p53-induced cell death in murine erythroleukemia cells. Mol Cell Biol 13: 711-719, 1993
11. Lowe SW, Schmitt EM, Smith SW: Osbome, B A and Jacks, T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362: 847-849, 1993.
12. Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML and Wyllie A H: Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362: 849-852, 1993.
13. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, Bigner SH, Davidson N, Baylin S, Devillee P, Glover T, Collins FS, Weston AN, Modali R, Harris CC and Vogelstein B: Mutation in the p53 gene occur in diverse human tumor types. Nature 342: 705-708, 1989.
14. Hollstein M, Sidransky D, Vogelstein B and Harris CC: p53 mutations in human cancers. Science 253: 49-52, 1991.
15. Milner J: DNA damage, p53 and anticancer therapies. Nature Med 1: 879-880, 1995.
16. Milner J: Flexibility: the key to p53 function? TIBS 20: 49-51, 1995.
17. Prives C: How loops, ß sheets, and a helices help us to understand p53. Cell 78: 543-546, 1994.
18. Shaw P, Bovey R, Tardy S, Sahli R, Sordat R and Costa J: Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc Natl Acad Sci USA 89: 4495-4499, 1992.
19. Lowe SW, Schmitt EM, Smith SW, Osbone BA and Jacks T: p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362: 847-849, 1993.
20. Iggo R, Gatter K, Bartek J, Lane D and Harris A: Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 335: 675-679, 1990.
21. Marks JR, Davidoff AM, Kerns BJ, Humphrey PA, Pence JC, Dodge RK, Clarke-Peason DL, Iglehart JD, Bast RC-Jr and Berchuck A: Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res 51: 2979-2984, 1991.
22. Dolcetti R, Doglioni C, Maestro R, Gasparotto D, Barzan L, Pastore A, Romanelli M and Boiocchi M: p53 over-expression is an early event in the development of human squamous-cell carcinoma of the larynx: genetic and prognostic implications. Int J Cancer 52: 178-182, 1992.
23. Pignatelli M, Stamp GWH, Kafiri G, Lane D and Bodmer WF: Overexpression of p53 nuclear oncoprotein in colorectal adenomas. Int J Cancer 50: 683-688, 1992.
24. Westa WH, Offerhaus GJA, Goodman SN, Slebos RJC, Polak M, Bass IO, Rodenhuis S and Hruban RH: Overexpression of the p53 tumor suppressor gene product in primary lung adenocarcinomas is associated with cigarette smoking. Am J Surg Pathol 17: 213-220, 1993.
25. Lassam NJ, From L and Kahn HJ: Overexpression of p53 is a late event in the development of malignant melanoma. Cancer Res 53: 2235-2238, 1993.
26. Ohashi M, Sugikawa E, Oda K and Nakanishi N: Inhibition of p53 protein phosphorylation by ellipticines: a possible anticancer mechanism. Proc Int Cancer Congress 16: 165-169, 1994.
27. Ohashi M, Sugikawa E and Nakanishi N: Inhibition of p53 phosphorylation by 9-hydroxyellipticine: a possible anticancer mechanism. Jpn J Cancer Res 86: 819-827, 1995.
28. Jasztold-Howorko R, Landras C, Pierre A: Synthesis and evaluation of 9-hydroxy-5-methyl-(and 5,6-dimethyl)-6H-pyrido[4,3b]carbazol-1-N-[(dialkyl amino)alkylcarboxamides, a new promising series of antitumor.olivacine derivatives. J Med Chem 37: 2445-2452, 1994.
29. Kunkel TA: Rapid and efficient site-specific mutagenesis without phenotypic selection. Proc Natl Acad Sci U.S.A. 82: 488-492, 1985.
30. Kunkel TA, Roberts JD and Zakour RA: Rapid and efficient site-specific mutagenesis without phenotypic selection. Method in Enzymology 154: 367-381, 1987.
31. Miyashita T, Krajewski S, Krafewska M, Wang HG, Lin HK, Liebermann DA, Hoffman B and Reed JC: Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9: 1799-1805, 1994.
32. Maniatis T, Fritsch EF and Sambrook J: Molecular Cloning-A Laboratory Manual. Cold Spring Harbor Laboratory 1982.
33. Hongestcclager M, Knofler M, Mullner EW, Ogris E, Wintersberger E and Wawra, E: Different regulation of thymidine kinase during the cell cycle of normal versus DNA tumor virus-transformed cells. J Biol Chem 269: 13836-13842, 1994.
34. Haupt Y, Rowan S, Shualian E, Vousden KH and Oren M: Induction of apoptosis in Hela cells by trans-activation-deficient p53. Genes Dev 9: 2170-2183, 1995.
35. Multon E, Riou J, LeFevre D, Ahomadegbe J and Riou G: Topoisomerase II-mediated DNA cleavage activity induced by ellipticines on the human tumor cell line N417. Biochem Pharmacol 38: 2077-2086, 1989.
36. Ohashi M and Oki T: Ellipticine and related anticancer agents. Exp Opin Ther Patents 6: 1285-1294, 1996.
37. Tewey KM, Rowe TC, Yang L, Halligan BD and Liu LF: ADR-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 226: 466-468, 1984.
38. El-Deiry WS, Harper W, O'Connor PM, Velculescu VE, Canman CE, Jackman J, Pietenpol JA, Burrell M, Hill DE, Wang Y, Wiman KG, Mercer WE, Kastan MB, Kohn KW, Elledge SJ, Kinzler KW and Vogelstein B: Wafl/cipl is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 54: 1169-1174, 1994.
39. Harper JW, Adami GR, Wei N, Keyomarsi K and Elledge SJ: The p21 Cdk-interacting protein CipI is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75: 805-816, 1993.
40. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW and Vogelstein B: WAF1, a potential mediator of tumor suppression. Cell 75: 817-825, 1993.
41. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R and Beach D: p21 is a universal inhibitor of cyclin kinases. Nature 366: 701-704, 1993.
42. Selvakmaran M, Lin H, Miyashita T, Wang HG, Krajewski S, Reed JC, Hoffman B and Liebermann D: Immediate early up-regulation of bax expression by p53 but not TGFß1: a paradigm for distinct apoptotic pathways. Oncogene 9: 1791-1798, 1994.
43. Chen X, Ko LJ, Jayaraman L and Prives C: p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells. Genes Dev 10: 2438-2451, 1996.